Phase I–II study of plitidepsin and dacarbazine as first-line therapy for advanced melanoma

c-Jun N-Terminal Kinase Phosphorylation Is a Biomarker of Plitidepsin Activity

(2013) María Muñoz-Alonso et al.   Marine Drugs

Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032)

(2011) Poulam M. Patel et al.   EUROPEAN JOURNAL OF CANCER

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Treatment for metastatic malignant melanoma: Old drugs and new strategies

(2009) Roger Mouawad et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Current systemic therapy for metastatic melanoma

(2009) Sanjiv S Agarwala   Expert Review of Anticancer Therapy

Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma

(2009) Tim Eisen et al.   MELANOMA RESEARCH

A Single-Institution Validation of the AJCC Staging System for Stage IV Melanoma

(2008) Heather B. Neuman et al.   ANNALS OF SURGICAL ONCOLOGY

Prognostic Factors That Determine the Long-Term Survival of Patients with Unresectable Metastatic Melanoma

(2008) Agop Y. Bedikian et al.   CANCER INVESTIGATION

Phase I Clinical and Pharmacokinetic Study of Plitidepsin as a 1-Hour Weekly Intravenous Infusion in Patients with Advanced Solid Tumors

(2008) M. A. Izquierdo et al.   CLINICAL CANCER RESEARCH